Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study
Journal of Clinical Oncology · 01.05.2026 · 44 (13) · 1238-1248
DOI: 10.1200/jco-25-01755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.05.2026. Verfasst von Rhoikos Furtwängler und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, University Hospital, Bern, Switzerland. Hauptthemen laut MEDLINE: Wilms Tumor, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP-RTSG) classifies blastemal-type Wilms tumor (WT) after preoperative chemotherapy as high-risk (HRWT). It remains unresolved whether residual absolute volume of blastema (AVB) functions as an independent prognostic factor across WT subtypes. MATERIALS AND METHODS AVB was calculated from preoperative tumor volume, necrosis percentage, and viable blastema using prospectively collected data from 3,459 patients with unilateral WT treated in the SIOP WT 2001 study between 2001 and 2018. Martingale residual plots defined AVB thresholds discriminating survival in localized HRWT, intermediate-/low-risk WT (IRWT/LRWT), and metastatic WT (stage IV). Complete AVB data were available for 1,802 patients (51.2%); 298 (16.5%) had stage IV disease. Of 1,504 patients with localized WT, 265 (17.6%) had HRWT, 1,203 (79.9%) had IRWT, and 36 (2.4%) had LRWT. RESULTS Multivariable Cox regression adjusted for age, sex, and local stage confirmed significantly worse survival for patients exceeding these AVB thresholds: (1) IRWT (≥20 mL): Hazard ratio for event-free survival (EFS) 2.93 (95% CI, 2.08 to 4.12) and overall survival (OS) 2.76 (95% CI, 1.32 to 5.77); (2) HRWT (≥100 mL): EFS 2.89 (95% CI, 1.59 to 5.26) and OS 3.25 (95% CI, 1.45 to 7.27); and (3) stage IV (≥10 mL): EFS 5.78 (95% CI, 3.65 to 9.17) and OS 4.59 (95% CI, 2.57 to 8.17). Patients above these thresholds had significantly lower 2-year EFS ( P < .0001). In stage II to III IRWT patients with AVB ≥20 mL, those treated with doxorubicin had superior EFS versus those without (87.6%, 95% CI, 81.5 to 94.1 v 69.2%, 95% CI, 59.8 to 80.1; P = .0064). CONCLUSION AVB after preoperative chemotherapy is a strong, independent predictor of both EFS and OS in WT across risk groups. An AVB of ≥20 mL identifies a clinically relevant subset of patients with IRWT who may benefit from intensified therapy with doxorubicin. These findings support the use of AVB as a stratification criterion in future SIOP-RTSG protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, University Hospital, Bern, Switzerland.
- Department of Pediatric Hematology and Oncology, Saarland University, Homburg/Saar, Germany.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Department of Pathology, Section of Paidopathology, University Bonn, Bonn, Germany.
- Department of Pathology, Sidra Medicine, Doha, Qatar.
- Department of Pathology, Hôpital Armand Trousseau, Assistance-Publique Hôpitaux de Paris, Sorbonne Université, Paris, France.
ORCID-Profile: Rhoikos Furtwängler, Rana Dandis, Harm van Tinteren, Nils Welter, Christian Vokuhl, Gordan Vujanic, Aurore Coulomb-L'Hermine, Jan Godzinski, Jens-Peter Schenk, Hervé Brisse, Manfred Gessler, Leo Kager, Patrick Melchior, Arnauld Verschuur, Beatriz de Camargo, Gema Ramirez-Villar, Filippo Spreafico, Jesper Brok, Tanzina Chowdhury, Marry M van den Heuvel-Eibrink, Norbert Graf
Zitieren
APA
Furtwängler, R., Dandis, R., van Tinteren, H., Welter, N., Vokuhl, C., Vujanic, G., Coulomb-L'Hermine, A., Godzinski, J., Schenk, J. P., Brisse, H., Gessler, M., Kager, L., Melchior, P., Warmann, S. W., Verschuur, A., de Camargo, B., Ramirez-Villar, G., Spreafico, F., Brok, J., …, & Graf, N. (2026). Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. Journal of Clinical Oncology, 44(13), 1238-1248. https://doi.org/10.1200/jco-25-01755
Vancouver
Furtwängler R, Dandis R, van Tinteren H, Welter N, Vokuhl C, Vujanic G, et al. Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. Journal of Clinical Oncology. 2026;44(13):1238-1248. doi:10.1200/jco-25-01755
BibTeX
@article{Furtwngler2026,
author = {Furtwängler, Rhoikos and Dandis, Rana and van Tinteren, Harm and Welter, Nils and Vokuhl, Christian and Vujanic, Gordan and Coulomb-L'Hermine, Aurore and Godzinski, Jan and Schenk, Jens-Peter and Brisse, Hervé and Gessler, Manfred and Kager, Leo and Melchior, Patrick and Warmann, Steven W and Verschuur, Arnauld and de Camargo, Beatriz and Ramirez-Villar, Gema and Spreafico, Filippo and Brok, Jesper and Chowdhury, Tanzina and van den Heuvel-Eibrink, Marry M and Graf, Norbert},
title = {Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {13},
pages = {1238--1248},
doi = {10.1200/jco-25-01755}
}
EUVIMED